Literature DB >> 14636304

Four peptides decrease the number of human pancreatic adenocarcinoma cells.

B A Vesely1, Q McAfee, W R Gower, D L Vesely.   

Abstract

BACKGROUND: Long-acting natriuretic peptide, vessel dilator, kaliuretic peptide and atrial natriuretic peptide are four peptide hormones synthesized by the same gene. Their main known biologic properties are sodium and water excretion and blood pressure lowering in both animals and humans. METHODS AND MATERIALS: These four peptide hormones, each at their 1-microm concentrations, were evaluated for their ability to decrease the number and/or proliferation of human pancreatic adenocarcinoma cells in culture at 24, 48, 72 and 96 h.
RESULTS: Vessel dilator, long-acting natriuretic peptide, kaliuretic peptide and atrial natriuretic peptide decreased the number of human pancreatic adenocarcinoma cells in culture by 65% (P<0.001), 47% (P<0.01), 37% (P<0.05) and 34% (P<0.05), respectively, within 24 h. This decrease was sustained without any proliferation of the cancer cells occurring in the 3 days following this decrease in number. The mechanism of these peptide hormones' decrease in cancer cell number and antiproliferative effects was a 83% (P<0.001) or greater inhibition of DNA synthesis but not owing to enhanced apoptosis, i.e. programmed cell death. The two known mediators of these peptide hormones' mechanism(s) of action, i.e. cyclic GMP and prostaglandin E2, inhibited DNA synthesis in these adenocarcinoma cells by 51% and 23%, respectively.
CONCLUSIONS: Four peptide hormones significantly decrease the number of pancreatic adenocarcinoma cells within 24 h and inhibit the proliferation of these cells for at least 96 h. Their mechanism of doing so is via inhibition of DNA synthesis mediated in part by cyclic GMP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14636304     DOI: 10.1046/j.1365-2362.2003.01262.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  11 in total

1.  Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via cyclic GMP.

Authors:  William R Gower; Brian A Vesely; Abdel A Alli; David L Vesely
Journal:  Int J Gastrointest Cancer       Date:  2005

Review 2.  The multifaceted role of natriuretic peptides in metabolic syndrome.

Authors:  Prasanna K Santhekadur; Divya P Kumar; Mulugeta Seneshaw; Faridoddin Mirshahi; Arun J Sanyal
Journal:  Biomed Pharmacother       Date:  2017-06-07       Impact factor: 6.529

3.  C-type natriuretic peptide receptor expression in pancreatic alpha cells.

Authors:  Matthew D Burgess; Kim D Moore; Gay M Carter; Abdel A Alli; Christopher S Granda; Hirohito Ichii; Camillo Ricordi; William R Gower
Journal:  Histochem Cell Biol       Date:  2009-04-08       Impact factor: 4.304

4.  Association between brain natriuretic peptide and distant metastases in advanced non-small cell lung cancer patients.

Authors:  Katsuhiro Masago; Shiro Fujita; Yosuke Togashi; Kaoru Irisa; Yuichi Sakamori; Yukimasa Hatachi; Akiko Fukuhara; Hiroki Nagai; Young Hak Kim; Tadashi Mio; Michiaki Mishima
Journal:  Oncol Lett       Date:  2011-01-21       Impact factor: 2.967

Review 5.  Designer natriuretic peptides.

Authors:  Candace Y W Lee; Hsiao Lieu; John C Burnett
Journal:  J Investig Med       Date:  2009-01       Impact factor: 2.895

6.  Cardiac hormones are potent inhibitors of secreted frizzled-related protein-3 in human cancer cells.

Authors:  William P Skelton; Michelle Skelton; David L Vesely
Journal:  Exp Ther Med       Date:  2012-11-12       Impact factor: 2.447

7.  Four cardiac hormones eliminate up to 82% of human medullary thyroid carcinoma cells within 24 hours.

Authors:  Ehrentraud J Eichelbaum; Brian A Vesely; Abdel A Alli; Ying Sun; William R Gower; David L Vesely
Journal:  Endocrine       Date:  2006-12       Impact factor: 3.925

8.  Cardiac Hormones Target the Ras-MEK 1/2-ERK 1/2 Kinase Cancer Signaling Pathways.

Authors:  David L Vesely
Journal:  Cancers (Basel)       Date:  2011-03-08       Impact factor: 6.639

Review 9.  Natriuretic peptide receptor A as a novel target for cancer.

Authors:  Jia Zhang; Zhilong Zhao; Jiansheng Wang
Journal:  World J Surg Oncol       Date:  2014-06-03       Impact factor: 2.754

10.  Atrial natriuretic peptide: a magic bullet for cancer therapy targeting Wnt signaling and cellular pH regulators.

Authors:  A Serafino; P Pierimarchi
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.